SCHEMBL5673256

SCHEMBL5673256

N#CC1(Cc2ccc(F)cc2)CCN(C(=O)COc2ccc(Cl)cc2-c2ccn[nH]2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
PROKR1 Q8TCW9 2/20 0.38
FPR2 P25090 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 1/20 0.38
ALOX12 P18054 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ENPP2 Q13822 1/20 0.37
ATXN2 Q99700 1/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CCR1 P32246 3/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
FPR3 P25089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634356 0.85 PTGDR2 (0.49) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4634285 0.83 CCR1 (0.52) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4634315 0.82 HTT (0.44) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4634701 0.82 MAPT (0.47) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4635597 0.82 PTGDR2 (0.45) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4633976 0.82 LMNA (0.53) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4634732 0.81 CYP2C9 (0.47) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4635564 0.81 CCR1 (0.43) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL4634630 0.81 HTT (0.43) HTTSMN1; SMN2GAAHPGDTSHR
SCHEMBL5673252 0.81 PTGDR2 (0.43) HTTSMN1; SMN2GAAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents CCR1, CCR2, CCR3 HTT 4424/4885PROKR1 168/4885FPR2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.